laquinimod 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| immunomodulators, both stimulant/suppressive and stimulant | 4825 | 248282-07-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Laquinimod is an immunomodulator developed by Teva for oral treatment for multiple sclerosis.
|
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 5, 2013 | Ministry of Health of the Russian Federation | Teva |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N07XX10 | NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS OTHER NERVOUS SYSTEM DRUGS Other nervous system drugs |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Relapsing remitting multiple sclerosis | indication | 426373005 | DOID:2378 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.66 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| D08938 | KEGG_DRUG |
| 248281-84-7 | SECONDARY_CAS_RN |
| CHEBI:134738 | CHEBI |
| CHEMBL66092 | ChEMBL_ID |
| CHEMBL2103814 | ChEMBL_ID |
| C476223 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7639 | IUPHAR_LIGAND_ID |
| DB06685 | DRUGBANK_ID |
| C1260208 | UMLSCUI |
| 8089 | INN_ID |
| 54677946 | PUBCHEM_CID |
| 908SY76S4G | UNII |
Pharmaceutical products:
None